Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Celcuity Inc. - Common Stock
(NQ:
CELC
)
112.63
-0.30 (-0.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celcuity Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
↗
April 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
Topics
Intellectual Property
Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast
April 26, 2021
MINNEAPOLIS, MN / ACCESSWIRE / April 26, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for...
From
Celcuity Inc.
Via
AccessWire
Stocks That Hit 52-Week Highs On Friday
↗
April 09, 2021
During the morning session on Friday, 178 stocks hit new 52-week highs. Noteworthy Points: Microsoft (NASDAQ:MSFT) was the largest firm on a market cap basis to set...
Via
Benzinga
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
↗
April 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (...
Via
Benzinga
Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling
April 12, 2021
- Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - - Synergistic cooperation between PI3K/mTOR and BCL signaling detected,...
From
Celcuity Inc.
Via
AccessWire
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
↗
April 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (...
Via
Benzinga
What's Happening With ATNF Stock And CELC Stock?
↗
April 12, 2021
180 Life Sciences Corp (NASDAQ: ATNF) shares are trading higher following insider buying from Marc Feldmann, a director on the company's board, and Jonathan Rothbard, the...
Via
Benzinga
55 Biggest Movers From Yesterday
↗
April 13, 2021
Gainers Celcuity Inc. (NASDAQ: CELC) jumped 29.4% to settle at $27.94. Celcuity shares climbed 51% on Friday after the company announced a worldwide licensing agreement with...
Via
Benzinga
42 Stocks Moving In Monday's Mid-Day Session
↗
April 12, 2021
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 44.8% to $8.05 after the company's 13D filing showed that Modell's Sporting Goods had reported a stake...
Via
Benzinga
51 Biggest Movers From Friday
↗
April 12, 2021
Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and...
Via
Benzinga
Mid-Afternoon Market Update: Dow Surges Over 100 Points; Provention Bio Shares Plunge
↗
April 09, 2021
Toward the end of trading Friday, the Dow traded up 0.42% to 33,645.90 while the NASDAQ rose 0.06% to 13,837.33. The S&P also rose, gaining 0.32% to 4,110.11. The U.S. has the...
Via
Benzinga
Topics
Stocks
Mid-Day Market Update: WD-40 Drops After Weak Q2 Results; Celcuity Shares Jump
↗
April 09, 2021
Midway through trading Friday, the Dow traded up 0.28% to 33,598.84 while the NASDAQ fell 0.16% to 13,806.77. The S&P also rose, gaining 0.13% to 4,102.64. The U.S. has the...
Via
Benzinga
Topics
Stocks
38 Stocks Moving In Friday's Mid-Day Session
↗
April 09, 2021
Gainers Celcuity Inc. (NASDAQ: CELC) shares jumped 64.5% to $23.54 after the company announced a worldwide licensing agreement with Pfizer to develop and commercialize...
Via
Benzinga
How A Pfizer Cancer Drug Pact Launched Celcuity Stock Into A Breakout
↗
April 09, 2021
Biotech stock Celcuity broke out and launched to near a two-year high Friday after it struck a licensing deal with Pfizer for a breast cancer treatment.
Via
Investor's Business Daily
Mid-Morning Market Update: Markets Open Higher; US Producer Prices Rise 1% In March
↗
April 09, 2021
Following the market opening Friday, the Dow traded up 0.29% to 33,487.00 while the NASDAQ rose 0.01% to 13,748.50. The S&P also rose, gaining 0.21% to 4,097.50. The U.S. has...
Via
Benzinga
Topics
Stocks
What's Going On With CELC Stock And PRVB Stock Today?
↗
April 09, 2021
Celcuity Inc (NASDAQ: CELC) shares are trading higher after the company announced a worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize...
Via
Benzinga
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
↗
April 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc...
Via
Benzinga
30 Stocks Moving in Friday's Pre-Market Session
↗
April 09, 2021
Gainers Celcuity Inc. (NASDAQ: CELC) rose 32.3% to $19.00 in pre-market trading after the company reported a worldwide licensing agreement with Pfizer to develop and...
Via
Benzinga
Celcuity Stock Moves Higher After Licensing Pact With Pfizer For Gedatolisib In Breast Cancer
↗
April 09, 2021
Celcuity Inc (NASDAQ: CELC) has entered into a global licensing agreement with Pfizer Inc (NYSE: PFE), granting Celcuity exclusive rights to...
Via
Benzinga
10 Stocks Moving In Thursday's After-Hours Session
↗
April 08, 2021
Gainers FuboTV (NYSE: FUBO) shares are trading higher after the company announced it acquired exclusive streaming rights to the Qatar World Cup 2022 Qualifying matches of South...
Via
Benzinga
Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
April 08, 2021
From
Celcuity Inc.
Via
Business Wire
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
April 08, 2021
From
Celcuity Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit